MOB-015
Onychomycosis (Toenail Fungus)
Key Facts
About Moberg Pharma
Moberg Pharma's mission is to commercialize proprietary pharmaceutical innovations by enhancing the delivery of established compounds, thereby reducing development risk and time-to-market. Its key achievement is the development and EU market approval of MOB-015, a novel topical treatment for onychomycosis now sold in Sweden and approved in 13 EU countries. The company's strategy focuses on leveraging its drug delivery platform to address high-unmet-need niches in dermatology, with a clear path toward commercialization and potential geographic expansion. Moberg operates as a lean, publicly-traded entity, utilizing capital markets to fund its focused growth initiatives.
View full company profileAbout Moberg Pharma
Moberg Pharma's mission is to commercialize proprietary pharmaceutical innovations by enhancing the delivery of established compounds, thereby reducing development risk and time-to-market. Its key achievement is the development and EU market approval of MOB-015, a novel topical treatment for onychomycosis now sold in Sweden and approved in 13 EU countries. The company's strategy focuses on leveraging its drug delivery platform to address high-unmet-need niches in dermatology, with a clear path toward commercialization and potential geographic expansion. Moberg operates as a lean, publicly-traded entity, utilizing capital markets to fund its focused growth initiatives.
View full company profileTherapeutic Areas
Other Onychomycosis (Toenail Fungus) Drugs
| Drug | Company | Phase |
|---|---|---|
| BiaPulse™ Device | BiaCure Therapies | Pre-clinical |